This HTML document is not a form. Its purpose is to display the information as found on the form for viewing purposes only. If you wish to use the form, you must use the alternate format below.
Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.
Product Name as per Drug Submission Application form (item 8):
Name of manufacturer/sponsor (Full legal name - no abbreviations) as per Drug Submission Application form (item 11):
Address of manufacturer/sponsor as per Drug Submission Application form (items 12-16):
Name/address of company (billing contact) to whom invoice is to be sent (if different from manufacturer/sponsor):
List all distinct drug products (route of administration/dosage form/condition of use/strength) you are applying to have reviewed. If you need more space, attach a separate sheet using same format.
Health Canada use only
DRSE Code Number
SAP Order Number
SAP Invoice Number
DSTS Control Number
Check the appropriate box to indicate the applicable submission, supplement or application fee.
|#||Submission Class||Submission Deadline||Fee ($)||Check one|
|1||New active substance||Submissions in support of a drug, excluding a disinfectant, that contains a medicinal ingredient not previously approved in a drug for sale in Canada and that is not a variation of a previously approved ingredient such as a salt, ester, enantiomer, solvate or polymorph.||315,741|
|2||Clinical or non-clinical data and chemistry and manufacturing data||Submissions based on clinical or non-clinical data and chemistry and manufacturing data that does not include a new active substance.||159,921|
|3||Clinical or non-clinical data only||Submissions based only on clinical or non-clinical data for a drug that does not include a new active substance.||74,639|
|4||Comparative studies||Submissions based on comparative studies (for example (e.g.) clinical or non-clinical data, bioavailability, pharmacokinetic and pharmacodynamic data) with or without chemistry and manufacturing data for a drug that does not include a new active substance.||45,113|
|5||Chemistry and manufacturing data only||Submissions based only on chemistry and manufacturing data for a drug that does not include a new active substance.||21,329|
|6||Published data only||Submissions based only on published clinical or non-clinical data for a drug that does not include a new active substance.||17,687|
|7||Switch from prescription to non-prescription status||Submissions based only on data that support the modification or removal of a medicinal ingredient listed in Schedule F to the Food and Drug Regulations (that is (i.e.) identical claim for existing drug).||42,949|
|8||Labelling only||Submissions of labelling material (i.e. does not include supporting clinical or non-clinical data or chemistry and manufacturing data).||2,873|
|9||Administrative submission||Submissions in support of a manufacturer or product name change.||297|
|10||Disinfectants||Submissions and applications that include data in support of a disinfectant.||3,975|
|11||DIN application - labelling standards||Applications attesting to compliance with a labelling standard or Category IV Monograph for a drug that does not include clinical or non-clinical data or chemistry and manufacturing data.||1,593|
Fees of $10,000 or less must be included with the submission, supplement or application. Sponsors will be invoiced for fees of more than $10,000.
If a sponsor has not completed its first full fiscal year on the day that the drug submission, supplement or application is filed, the sponsor is eligible for a two-year deferral of payment from the day the drug submission, supplement or application is filed. In order to qualify for the deferral period, a statement signed by the individual responsible for the sponsor's financial affairs specifying the commencement date of the fiscal year must be submitted with the submission, supplement or application. At the end of the two-year period, the sponsor must pay all of the applicable fees.
Check the applicable boxes:
When applying for a fee remission, the necessary documentation and the remission processing fee of $521 must accompany the submission, supplement or application. Failing to do so will result in the rejection of the fee remission application.
In order to be eligible for a remission, the full fee indicated in section 3 must be more than 10% of the anticipated gross revenue from sales of the product in Canada during the fee verification period of three years. Refer to the Guidance Document - Fees for the Review of Drug Submissions and Applications for further information on fee remissions.
Check the applicable boxes:
When applying for a remission, review fees must not be included with the submission, supplement or application. Sponsors will be invoiced for the applicable fee.
For detailed payment instructions please refer to How to Pay Fees.